drugset / Trial / NCT03330561
PRS-343 in HER2-Positive Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
Timeline
- Start
- 2017-09-13
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinrebafusp alfa | Other / unclassified | — | Intravenous |